+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID06220032

Preventing Heart Damage with Dexrazoxane in Diffuse Large B-Cell Lymphoma Patients Receiving R-CHOP Chemotherapy A National Randomized Trial

Led by Stichting Hemato-Oncologie voor Volwassenen Nederland · Updated on 2026-09-23

324

Participants Needed

25

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating whether dexrazoxane can prevent heart damage caused by anthracycline chemotherapy in patients with diffuse large B-cell lymphoma DLBCL. This condition, known as anthracycline-induced cardiac dysfunction AICD, can lead to irreversible heart muscle damage and heart failure. Patients with DLBCL are at higher risk of AICD due to their treatment regimen and longer survival, making prevention of heart damage important. This is a national phase III randomized controlled trial conducted across multiple hospitals in the Netherlands. Participants will receive six cycles of R-CHOP21 chemotherapy, which includes rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. They will be randomly assigned to either receive dexrazoxane intravenously before doxorubicin infusion or to receive standard treatment without dexrazoxane. Some patients with double hit lymphoma may receive lenalidomide as part of their regimen. The trial does not use placebo due to the nature of dexrazoxane. Cardiac function will be monitored using echocardiography before treatment and at 4 and 12 months after treatment starts. Participants will undergo heart function tests, metabolic remission assessments, survival evaluations, blood biomarker tests, and quality of life questionnaires during the study. The main outcome is the occurrence of significant heart function decline within 12 months. The study will also assess whether dexrazoxane affects cancer treatment effectiveness. Participants will be followed for at least one year to monitor heart health and cancer status, with regular visits for evaluations and treatment administration.

CONDITIONS

Brief Title

Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma

Research Team

A

A. van Rhenen, MD

M

M.P.M. Linschoten, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here